Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Founded in 1989, Bristol-Myers Squibb is a diversified global health and personal care company.

The company concentrates its pharmaceutical research and development efforts in the following ten critical disease areas: oncology, affective (psychiatric) disorders, Alzheimer's/dementia, atherosclerosis/thrombosis, diabetes, hepatitis, HIV/AIDS, obesity, rheumatoid arthritis and related diseases and solid organ transplant. However, BMS continues to analyse and may selectively pursue promising leads in other areas.

BMS' Oncology Therapeutics Network (OTN) segment, a leading speciality distributor of oncology drugs, supportive care products and related supplies to office-based oncologists in the US, was acquired in May 2005 by One Equity Partners.